Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that at the Annual General Meeting held earlier today, all resolutions were duly passed.
For further information, please contact:
|
Advanced Oncotherapy Plc |
|
|
Dr. Michael Sinclair, Executive Chairman |
Tel: +44 20 3617 8728 |
|
Nicolas Serandour, CEO |
|
|
Stockdale Securities (Nomad & Joint Broker) |
|
|
Antonio Bossi / David Coaten |
Tel: +44 20 7601 6100 |
|
Stifel Nicolaus Europe (Joint Broker) |
|
|
Jonathan Senior / Ben Maddison |
Tel: +44 20 7710 7600 |
|
Walbrook PR (Financial PR & IR) |
Tel: +44 20 7933 8780 or avo@walbrookpr.com |
|
Paul McManus / Anna Dunphy |
Mob: +44 7980 541 893 / Mob: +44 7876 741 001 |